Amy Corneli1, Brian Perry, Kevin McKenna, Kawango Agot, Khatija Ahmed, Jamilah Taylor, Fulufhelo Malamatsho, Jacob Odhiambo, Joseph Skhosana, Lut Van Damme. 1. *Social and Behavioral Health Sciences, FHI 360, Durham, NC; †Currently, Department of General Internal Medicine, Duke University, Durham, NC; ‡Currently, Duke Clinical Research Institute, Duke University, Durham, NC; §Impact Research and Development Organization, Kisumu, Kenya; ‖Setshaba Research Centre, Soshanguve, South Africa; ¶Clinical Sciences, FHI 360, Durham, NC; and #The Bill & Melinda Gates Foundation, Seattle, WA.
Abstract
BACKGROUND: FEM-PrEP-a clinical trial of daily, oral emtricitabine/tenofovir disoproxil fumarate for HIV prevention among women in sub-Saharan Africa-did not show a reduction in HIV acquisition because of low adherence to the study pill. We conducted a follow-up study to identify reasons for nonadherence. METHODS: Qualitative, semistructured interviews (n = 88) and quantitative, audio computer-assisted self-interviews (n = 224) were conducted with former FEM-PrEP participants in Bondo, Kenya, and Pretoria, South Africa. Thematic analysis was used to analyze the qualitative data, and descriptive statistics were used to describe audio computer-assisted self-interviews responses. Data are presented within the 5 categories of Ickovics' and Meisler's conceptual framework on adherence: (1) the individual, (2) trial characteristics and study pill regimen, (3) patient-provider relationship, (4) clinical setting, and (5) the disease. RESULTS: Participants' explanations for nonadherence were primarily situated within 3 of the framework's 5 categories: (1) the individual, (2) trial characteristics and study pill regimen, and (3) the disease. Concerns about the investigational nature of the drug being tested and side effects were the prominent reasons reported for nonadherence. Participants also described being discouraged from taking the study pill by members of the community, their sexual partners, and other participants, primarily because of these same concerns. Limited acceptability of the pill's attributes influenced nonadherence for some participants as did concerns about HIV-related stigma. In addition, many participants reported that others continued in FEM-PrEP while not taking the study pill because of the trial's ancillary benefits and visit reimbursement-factors related to the clinical setting. Negative patient-provider relationships were infrequently reported as a factor that influenced nonadherence. CONCLUSIONS: Despite substantial study staff engagement with participants and communities, concerns about the study pill and discouragement from others seemed to have influenced nonadherence considerably. Alternative study designs or procedures and enhanced community engagement paradigms may be needed in future studies.
RCT Entities:
BACKGROUND:FEM-PrEP-a clinical trial of daily, oral emtricitabine/tenofovir disoproxil fumarate for HIV prevention among women in sub-Saharan Africa-did not show a reduction in HIV acquisition because of low adherence to the study pill. We conducted a follow-up study to identify reasons for nonadherence. METHODS: Qualitative, semistructured interviews (n = 88) and quantitative, audio computer-assisted self-interviews (n = 224) were conducted with former FEM-PrEP participants in Bondo, Kenya, and Pretoria, South Africa. Thematic analysis was used to analyze the qualitative data, and descriptive statistics were used to describe audio computer-assisted self-interviews responses. Data are presented within the 5 categories of Ickovics' and Meisler's conceptual framework on adherence: (1) the individual, (2) trial characteristics and study pill regimen, (3) patient-provider relationship, (4) clinical setting, and (5) the disease. RESULTS:Participants' explanations for nonadherence were primarily situated within 3 of the framework's 5 categories: (1) the individual, (2) trial characteristics and study pill regimen, and (3) the disease. Concerns about the investigational nature of the drug being tested and side effects were the prominent reasons reported for nonadherence. Participants also described being discouraged from taking the study pill by members of the community, their sexual partners, and other participants, primarily because of these same concerns. Limited acceptability of the pill's attributes influenced nonadherence for some participants as did concerns about HIV-related stigma. In addition, many participants reported that others continued in FEM-PrEP while not taking the study pill because of the trial's ancillary benefits and visit reimbursement-factors related to the clinical setting. Negative patient-provider relationships were infrequently reported as a factor that influenced nonadherence. CONCLUSIONS: Despite substantial study staff engagement with participants and communities, concerns about the study pill and discouragement from others seemed to have influenced nonadherence considerably. Alternative study designs or procedures and enhanced community engagement paradigms may be needed in future studies.
Authors: Elizabeth T Montgomery; Jonathan Stadler; Sarita Naidoo; Ariana W K Katz; Nicole Laborde; Morgan Garcia; Krishnaveni Reddy; Leila E Mansoor; Juliane Etima; Chifundo Zimba; Miria Chitukuta; Lydia Soto-Torres Journal: AIDS Date: 2018-07-17 Impact factor: 4.177
Authors: Whitney S Rice; Kristi L Stringer; Maira Sohail; Kaylee B Crockett; Ghislaine C Atkins; Kachina Kudroff; D Scott Batey; Joshua Hicks; Janet M Turan; Michael J Mugavero; Bulent Turan Journal: AIDS Behav Date: 2019-11
Authors: Rebecca Giguere; Christine Tagliaferri Rael; Alan Sheinfil; Ivan C Balán; William Brown; Titcha Ho; Curtis Dolezal; Cheng-Shiun Leu; Albert Liu; Kenneth H Mayer; Javier R Lama; Ian McGowan; Alex Carballo-Diéguez; Ross D Cranston Journal: AIDS Behav Date: 2018-02
Authors: Ariane van der Straten; Erica N Browne; Mary Kate Shapley-Quinn; Elizabeth R Brown; Krishnaveni Reddy; Rachel Scheckter; Lydia Soto-Torres; Thesla Palanee-Phillips; Jared M Baeten; Barbara Mensch Journal: J Acquir Immune Defic Syndr Date: 2019-07-01 Impact factor: 3.731
Authors: Iván C Balán; Rebecca Giguere; William Brown; Alex Carballo-Diéguez; Stephanie Horn; Craig W Hendrix; Mark A Marzinke; Ratiya Pamela Kunjara Na Ayudhya; Karen Patterson; Jeanna M Piper; Ian McGowan; Javier R Lama; Ross D Cranston Journal: AIDS Behav Date: 2018-03